About Biogen
Biogen is a publicly listed company based in Cambridge (United States) founded in 1978 by Heinz, Phillip Allen Sharp, Walter Gilbert, and Charles Weissmann. Therapies for neurodegenerative and immunology disorders are developed. It operates on a Direct-to-Consumer (D2C) and Professional Services model. Biogen has raised $80 million across 2 funding rounds from investors including PRIMECAP. The company has 7,610 employees. Biogen has completed 13 acquisitions, including Apellis Pharmaceuticals, Conforma and Convergence Pharma. Its chief executive, as recorded, is Christopher Viehbacher. Its website biogen.com draws about 169 thousand monthly visits. Its Indian entity Biogen Capability Center India Private Limited reported revenue of ₹66.34 Cr. Biogen offers products and services including Alzheimer's Disease Therapies, Multiple Sclerosis Treatments, and Spinal Muscular Atrophy Solutions. Its focus areas include Biotechnology and Neurological Disorders. Its competitors include Neurocrine, PTC Therapeutics and ADMA Biologics; 3 of its 3 listed competitors have raised funding.
Company details
Biogen is focused on the research and development of innovative therapies for neurological and neurodegenerative diseases. Areas of expertise include Alzheimers disease, multiple sclerosis, and spinal muscular atrophy. Solutions are provided through clinical trials and early access programs. The company operates globally, addressing health equity and access. Sectors served include biotechnology and healthcare with a commitment to transformative medicines.
- Indian entity revenue₹66.34 Cr
FY 2025 · +220% YoY
- Indian entity net profit₹5.26 Cr
FY 2025 · 8% margin
- Indian entity EBITDA₹8.84 Cr
FY 2025 · 13% margin
- Total Equity Funding$80M (USD)
in 2 rounds
- Investors
- Employee Count7,610
- Investments & AcquisitionsApellis Pharmaceuticals
& 12 more
Associated legal entities of Biogen
Biogen operates through Biogen Capability Center India Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2025) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Biogen Capability Center India Private Limited CIN U62013KA2023FTC173057 | Active | 30 Apr 2023 | Bangalore, Karnataka | ₹66.3 Cr | 34 | 2 | View details |
Products & Services of Biogen
Biogen offers a comprehensive portfolio of products and services, including Alzheimer's Disease Therapies, Multiple Sclerosis Treatments, and Spinal Muscular Atrophy Solutions.
Therapies for Alzheimer's disease are developed and provided.
Treatments for multiple sclerosis are researched and offered.
Solutions for spinal muscular atrophy are created and distributed.
Apps and channels of Biogen
its YouTube channel バイオジェン has 1.43K subscribers and 30 videos.
Videos from Biogen
The most watched videos on Biogen's YouTube channel, バイオジェン (1.43K subscribers). Click a video to play it here.
More on バイオジェン.
Funding Insights of Biogen
Biogen has successfully raised a total of $80M across 2 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $80M
- Total Rounds 2
- First Round $80M
(Feb 1983)
- Investors Count 1
All 2 funding rounds of Biogen with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb 2024 | Post-IPO | – | – | ||
| Feb 1983 | $80M | Private Equity Round | – | – | – |
1 investors in total: 1 institutional.
Investors in Biogen
Biogen has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include PRIMECAP.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Manages mutual funds through fundamental stock selection and long-term horizons. | 1983 | primecap.com | Pasadena, United States |
Investor details for Biogen
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Board of directors of Biogen Capability Center India Private Limited (Biogen)
Biogen Capability Center India Private Limited is the primary company behind Biogen. The board of Biogen Capability Center India Private Limited currently have 2 directors; the longest-serving is Frederick Lawson, appointed in 2023. 2 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Frederick Lawson DIN 07656059 | Director | 30 Apr 2023 | 3 yrs 6 mo | Biogen Capability Center India Private Limited |
| Arijit Mukherjee DIN 10519644 | Director | 29 Feb 2024 | 2 yrs 8 mo | Biogen Capability Center India Private Limited |
People of Biogen
902 people are tracked at Biogen (451 in leadership, 10 in board & advisors, 441 in team); the tracked headcount is 7,610.
| Name | Role | Group |
|---|---|---|
Heinz | Co-Founder | Leadership |
Phillip Allen Sharp | Co-Founder | Leadership |
Walter Gilbert | Co-Founder | Leadership |
Charles Weissmann | Co-Founder | Leadership |
Christopher Viehbacher | CEO | Leadership |
Michael Schindelar | Sr. Director Development Asset Lead | Leadership |
Andrei Huang | Head Of HPC | Leadership |
Jane Grogan | Head, Research | Leadership |
Katherine Dawson | Senior Vice President, Therapeutics Development Unit; Director, Biogen Foundation | Leadership |
Maria F. | Head Of People Relations And Governance | Leadership |
Holly M. Brothers | Associate Medical Director | Leadership |
Jerome Hanna | Executive Medical Director, Multiple Sclerosis Clinical Development | Leadership |
Rosalind McCully | Associate Director, CMC Global Regulatory Lead | Leadership |
Devendra Singh | Associate Director - Ma&r Insights & Patient Access | Leadership |
Emanuel de Duonni | Global Asset Head | Skyclarys & Friedreich’s Ataxia | Executive Director | Leadership |
Chris Helal | Head Of Synthetic Medicine Design | Leadership |
Samir Koirala | Head Of Genetic, Neurodevelopmental & Epilepsy Disorders Research | Leadership |
Karuna Beecharaju | Associate Director, Commercial Information Management | Leadership |
Masami Hayami | Japan HR Head | Leadership |
Alejandro Parra | Marketing Operations Lead - INT Partner Markets | Leadership |
882 more people are available in the full profile.
Complete people profiles for Biogen
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Biogen
Biogen is a publicly listed company on the NASDAQ with ticker symbol BIIB in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date16 Sep 1991
- Listed onNASDAQ: BIIB
- Listed entityBiogen Inc.
- Exchange sectorHealth technology
- ISINUS09062X1037
- Share price$228.90 (-0.22% on the day) · 2026-10-13
- Market capitalisation$33.82B
- Price to earnings40.5
- EPS (diluted, trailing year)$5.65
- Volume (last session)1,049,196
Financials of Biogen
Figures of Biogen Capability Center India Private Limited, the primary company behind Biogen, for FY 2025. Revenue was ₹66.34 Cr (+220% year on year). Net profit was ₹5.26 Cr (8% margin). EBITDA was ₹8.84 Cr (13% margin).
- ₹66.34 CrRevenue · FY 2025 · +220% YoY
- ₹5.26 CrNet profit · 8% margin
- ₹8.84 CrEBITDA · 13% margin
- ₹1 LakhPaid-up capital
- 34Employees (provident fund records)
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $9.53B | $1.29B | $3.32B |
| 2024 | $9.27B | $1.63B | $2.80B |
| 2023 | $9.42B | $1.16B | $2.13B |
| 2022 | $9.43B | $3.05B | $2.79B |
| 2021 | $10.40B | $1.56B | $3.35B |
Balance sheet, profit and loss, cash flow and ratios of Biogen Capability Center India Private Limited are on its company page.
Detailed financial statements for Biogen
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Biogen
Biogen has strategically engaged in corporate development activities, having acquired 13 companies. Notable acquisitions include Apellis Pharmaceuticals, Conforma and Convergence Pharma.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Small molecule therapies for immunology unmet needs are developed. | raythera.com | San Diego, United States | 2023 | Jun 2026 | $1B | |
Complement system is targeted to treat autoimmune and inflammatory diseases. | apellis.com | Crestwood, United States | 2008 | Mar 2026 | $5.6B | |
Precision medicines for autoimmune and inflammatory diseases are developed. | hibio.com | Foshan, China | 2021 | May 2024 | $1.15B | |
Small molecules for melanoma, pulmonary hypertension, friedreich’s ataxia, mitochondrial myopathies and cataract surgery patients | reatapharma.com | Irving, United States | 2002 | Jul 2023 | •••• | |
Gene therapies for inherited retinal diseases are developed. | nightstartx.com | London, United Kingdom | 2013 | Mar 2019 | $877M | |
Intravenous formulation for acute central nervous system conditions such as stroke (ischemic and hemorrhagic), traumatic brain injury. | remedypharmaceuticals.com | New York, United States | 2004 | May 2017 | $120M | |
Novel analgesics are developed for chronic pain via ion-channel modulation. | convergencepharma.com | Babraham, United Kingdom | 2010 | Jan 2015 | $200M | |
Drugs for fibrosis and organ failure are developed by Stromedix. | stromedix.com | Cambridge, United States | 2006 | Feb 2014 | $75M | |
Infusion medication for infection prevention is developed and provided. | tysabri.com | Durham, United States | 2002 | Feb 2013 | •••• | |
Therapeutic proteins for chronic diseases like hemophilia are developed. | syntnx.com | Waltham, United States | 1999 | Jan 2007 | •••• |
Complete acquisition details for Biogen
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Biogen
14 dated milestones of Biogen across 48 years, from founding to its latest funding, stage changes and deals.
- Founded Biogen is founded.
- Funding First funding round of $80.0M.
- IPO Lists on the stock exchange (IPO).
- Acquisition Acquires Syntonix Pharmaceuticals.
- Acquisition Acquires TYSABRI.
- Acquisition Acquires Stromedix.
- Acquisition Acquires Convergence Pharma.
- Acquisition Acquires Remedy Pharmaceuticals.
- Acquisition Acquires Nightstar.
- Acquisition Acquires Reata Pharma.
- Funding Latest funding round, Post-IPO,.
- Acquisition Acquires HIBio.
- Acquisition Acquires Apellis Pharmaceuticals.
- Acquisition Acquires RayThera.
Competitors of Biogen
Biogen has 3 listed competitors in our database, 3 of them funded. They include Neurocrine, PTC Therapeutics and ADMA Biologics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| neurocrine.com | 1992 | San Diego, United States | $10M | 1,400 | Developer of small molecule therapeutics for endocrine and CNS disorders | |
| ptcbio.com | 1998 | South Plainfield, United States | $248.1M | 995 | Small molecule drugs for rare diseases are developed. | |
| admabiologics.com | 2005 | Ramsey, United States | $17.55M | 498 | Plasma-based biologics are developed for immune deficiency and infectious diseases. |
Detailed competitors of Biogen
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Biogen
The website of Biogen (biogen.com) receives about 169.3K visits a month and ranks #201,824 among all websites worldwide, #6,538 in Medicine.
- Monthly visits169.3K
▲ 14.7% vs previous month
- Unique visitors57.8K
per month
- Global rank#201,824
among all websites
- Category rank#6,538
Health · Medicine
- Bounce rate45%
- Pages per visit5.9
- Average visit4 min 54 sec
- DevicesDesktop 65% · Mobile 35%
Websites whose visitors overlap most with Biogen. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| bosley.com | 100% | 296.8K | #204,627 | View details | |
| gilead.com | 99% | 576.5K | #103,109 | View details | |
| vrtx.com | 92% | 342.2K | #151,023 | View details | |
aan.com | aan.com | 85% | #98,454 | – | |
| nejmcareercenter.org | 85% | #301,466 | View details | ||
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 40 similar websites and full traffic analytics for Biogen
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 40 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Immunology & Cancer Therapeutics
3 companies that operate in the same segment as Biogen (Immunology & Cancer Therapeutics) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | |||
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Biogen
Complete news archive for Biogen
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Biogen
Biogen was founded in 1978 and raised its 1st funding round 5 years after it was founded.
Biogen is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Christopher Viehbacher is the CEO of Biogen, as recorded in our data.
Biogen is a funded company, having raised a total of $80M across 2 funding rounds to date. The company's 1st funding round was a Private Equity Round of $80M, raised on Feb 1983.
Biogen has 7,610 employees.
The primary company behind Biogen, Biogen Capability Center India Private Limited, reported revenue of ₹66.34 Cr for FY 2025, up 220% year on year.
Biogen is focused on the research and development of innovative therapies for neurological and neurodegenerative diseases. Areas of expertise include Alzheimers disease, multiple sclerosis, and spinal muscular atrophy. Solutions are provided through clinical trials and early access programs. The company operates globally, addressing health equity and access. Sectors served include biotechnology and healthcare with a commitment to transformative medicines.
Biogen's top competitors include ADMA Biologics, PTC Therapeutics and Neurocrine.
Biogen offers Alzheimer's Disease Therapies, Multiple Sclerosis Treatments, and Spinal Muscular Atrophy Solutions.
Yes, Biogen is publicly traded on NASDAQ under the ticker symbol BIIB.
Biogen has made 13 acquisitions, including Apellis Pharmaceuticals, Conforma, and Convergence Pharma.
Biogen has 1 investor. Key investors include PRIMECAP.